Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QCC374 in Pulmonary Arterial Hypertension
NCT02927366Phase 2Terminated
- Sponsor
- Novartis
- Start
- Sep 2017
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of QCC374 in pulmonary arterial hypertension (PAH), sponsored by Novartis. Started Sep 2017; status: terminated.
02
Drugs
QCC374
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT02927366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02927366.